RANI
Rani TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
RT-114 Phase 1 progress, possible Chugai milestone conversion and improved strategic leadership could validate RaniPill and support substantial upside from the depressed share price.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
CFO transition and limited external coverage increase execution and information risk.
Momentum
85
Value
41
Sentiment
57
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.75 · Bull $1.35 · Bear $0.25
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $7.50
Why
Momentum85 · Δ7d -
Value41 · Δ7d -0.1
Sentiment57 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
57
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 84.6 / Value 41.1 / Sentiment 56.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$95.08M
Beta
0.44
Shares Out
112.39M
P/E (TTM) · Derived
-1.9
P/S (TTM)
137.72
P/FCF (TTM) · Derived
-2.79
Rev YoY
+893.0%
EPS YoY
-82.0%
Gross Margin
+74.4%
Op Margin
-3727.8%
Net Debt
-$45.59M
Current Ratio
3.40
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology